// App-Quantinova.ai

: Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study

Researchers

Presenter

  • Philippe Armand

Principal Investigators

  • Andreas Engert

  • Anas Younes

  • Hun Ju Lee

  • Armando Santoro

  • Pier Luigi Zinzani

  • John M. Timmerman

  • Graham P. Collins

  • Radhakrishnan Ramchandren

  • Jonathon B. Cohen

  • Jan Paul De Boer

  • Kerry J Savage

  • John Kuruvilla

  • Marek Trnen

  • Margaret A. Shipp

  • Mariana Sacchi

  • Anne Sumbul

  • Stephen M. Ansell

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Cologne, Cologne, DE, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Hematology, Humanitas Cancer Center, Humanitas Research Hospital, Milano, Italy

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • University of California, Los Angeles, Los Angeles, CA

  • Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom

  • Barbara Ann Karmanos Cancer Institute, Detroit, MI

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands

  • BC Cancer, Vancouver, Canada

  • University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Mayo Clinic, Rochester, MN

Locations

  • United States

  • Germany

  • Italy

  • United Kingdom

  • Netherlands

  • Canada

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Single Arm

  • Multinational

  • Cohort

Phase

  • II

Study Id's

  • NCT02181738

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved